Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
To evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer
Locally Advanced Cervical Cancer
BIOLOGICAL: Camrelizumab|RADIATION: radiotherapy|DRUG: Albumin Paclitaxel|DRUG: Cisplatin
Objective response rate (ORR), The objective remission rate refers to the proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases of complete remission and partial remission, 2 year
Progression-free survival（PFS）, The period of time between when a patient with neoplastic disease receives treatment and when the disease progresses or death from any cause occurs, 2 year|Overall survival（OS）, The time from the patient's confirmation of the disease to death due to any cause, 2 year|Disease control rate（DCR）, Refers to the proportion of patients whose tumors have shrunk or stabilized for a certain period of time, including complete remission (CR), partial remission (PR) and stable (SD) cases, 2 year|Adverse reaction rate, Harmful and unrelated reactions that occur when normal doses of drugs are used to prevent, diagnose, treat diseases or regulate physiological functions, 2 year|Patient quality of life, Comprehensively evaluate the pros and cons of life by filling in the questionnaire, 2 year
This study is a single-arm, single-center, open, prospective phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer.